Please use this identifier to cite or link to this item: https://doi.org/10.1001/jama.2012.17312
Title: Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: The TRILOGY ACS platelet function substudy
Authors: Gurbel, P.A.
Erlinge, D.
Ohman, E.M.
Neely, B.
Neely, M.
Goodman, S.G.
Huber, K.
Chan, M.Y. 
Cornel, J.H.
Brown, E.
Zhou, C.
Jakubowski, J.A.
White, H.D.
Fox, K.A.A.
Prabhakaran, D.
Armstrong, P.W.
Tantry, U.S.
Roe, M.T.
Issue Date: 7-Nov-2012
Citation: Gurbel, P.A., Erlinge, D., Ohman, E.M., Neely, B., Neely, M., Goodman, S.G., Huber, K., Chan, M.Y., Cornel, J.H., Brown, E., Zhou, C., Jakubowski, J.A., White, H.D., Fox, K.A.A., Prabhakaran, D., Armstrong, P.W., Tantry, U.S., Roe, M.T. (2012-11-07). Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: The TRILOGY ACS platelet function substudy. JAMA - Journal of the American Medical Association 308 (17) : 1785-1794. ScholarBank@NUS Repository. https://doi.org/10.1001/jama.2012.17312
Abstract: Context: The relationship of platelet function testing measurements with outcomes in patients with acute coronary syndromes (ACS) initially managed medically without revascularization is unknown. Objective: To characterize the differences and evaluate clinical outcomes associated with platelet reactivity among patients with ACS treated with clopidogrel or prasugrel. Design, Setting, and Patients: Patients with medically managed unstable angina or non-ST-segment elevationmyocardial infarction were enrolled in the TRILOGY ACS trial (2008 to 2011) comparing clopidogrel vs prasugrel. Of 9326 participants, 27.5% were included in a platelet function substudy: 1286 treated with prasugrel and 1278 treated with clopidogrel. Interventions: Aspirin with either prasugrel (10 or 5 mg/d) or clopidogrel (75 mg/d); those 75 years or older and younger than 75 years but who weighed less than 60 kg received a 5-mg prasugrel maintenance dose. Main Outcome Measures: Platelet reactivity, measured in P2Y12 reaction units (PRUs), was performed at baseline, at 2 hours, and at 1, 3, 6, 12, 18, 24, and 30 months after randomization. The primary efficacy end point was a composite of cardiovascular death, myocardial infarction, or stroke through 30 months. Results: Among participants younger than 75 years and weighing 60 kg or more, the median PRU values at 30 days were 64 (interquartile range [IQR], 33-128) in the prasugrel group vs 200 (IQR, 141-260) in the clopidogrel group (P
Source Title: JAMA - Journal of the American Medical Association
URI: http://scholarbank.nus.edu.sg/handle/10635/126837
ISSN: 00987484
DOI: 10.1001/jama.2012.17312
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.